Glenmark made a licensing agreement with APC Therapeutics

| By | Cancer Drugs, Drug Development, Glenmark

Glenmark Pharmaceuticals informed it has entered into an agreement with Boston‐based biopharmaceutical firm APC Therapeutics to in-license the latter’s novel immune-oncology molecule. The financial details of the details were not disclosed.

However, under the  terms  of  the agreement, Glenmark will  in-license  the  product  from APC Therapeutics, and manage all  clinical  development  including  regulatory  filings and  commercialisation  worldwide. Glenmark will have exclusive rights on the drug.

APC Therapeutics will receive development milestones and sales royalty payments. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

“This asset adds to our robust biologics pipeline of targeted IO therapies,” said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals. “The mechanism of action of Antigen Presenting Cell (APC) biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful immunologic responses to tumors that may lead to deeper and more durable responses to treatment.”

“Glenmark  is  an  ideal  partner  to  advance  such  an  important  scientific  breakthrough  treatment  to patients with cancer,” said Vinod Patel and Venkateshwar Reddy, the co‐founders of APC Therapeutics. “This  partnership  is  strategically  significant  for  APC  Therapeutics  as  it  validates  and  advances  our commitment to bring the right immunotherapies to the right patient populations,”  the cofounders added.

The global oncology market is growing exponentially and projected  to exceed $150 billion by 2020, according to figures from IMS Health. Driving this growth is the transition from short‐term cytotoxic treatments towards precision medicines, most notably immune-oncology agents providing substantial increase in long‐term survival. Because of these improvements, immune-oncology is one of the most promising and fastest growing areas of cancer treatment and research.

Glenmark is one among very few companies with a drug discovery programme. The company has a diverse pipeline with several  compounds  in  various  stages  of  clinical  development,  primarily  focused  in  the  areas  of oncology,  respiratory,  and  dermatology  and  includes  three  bispecific  monoclonal  antibodies (bsABs) and an antibody‐based agonist targeting OX40R. The immuno‐oncology pipeline currently includes four candidates being studied in a wide‐range of tumor types.

SOURCE: moneycontrol
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.